← Back to Clinical Trials
Recruiting NCT06104852

NCT06104852 Triage Survey for Neurology Research Eligibility

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06104852
Status Recruiting
Phase
Sponsor Adams Clinical
Condition Alzheimer Disease
Study Type OBSERVATIONAL
Enrollment 600 participants
Start Date 2023-06-02
Primary Completion 2027-06-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
SurveyOptional Medication Washout

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 600 participants in total. It began in 2023-06-02 with a primary completion date of 2027-06-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.

Eligibility Criteria

Inclusion Criteria: * Participant and study partner (when applicable) have signed an ICF prior to study-specific procedures being performed. * Participant and study partner (when applicable) are at least 18 years old. Exclusion Criteria: * Participant lacks the language skills or cognitive ability to understand the screening process. * Participant is pregnant, breast-feeding, or planning to become pregnant. * History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results. * Participant represents an acute suicidal risk, as defined as a "yes" response to ideation on Columbia-Suicide Severity Rating Scale questions 4 or 5, or answer "yes" to behavior questions within 90 days of screening. * Moderate or severe substance use disorder within 90 days prior to screening, according to DSM-5 criteria that in the investigator's opinion could pose undue risk to the participant. * Any condition that in the investigator's opinion makes a participant unsuitable for the study. * Currently employed by Adams Clinical or a first-degree relative of an employee working on this study.

Contact & Investigator

Central Contact

Sarah J Starling, PhD

✉ sstarling@adamsclinical.com

📞 6177448542

Frequently Asked Questions

Who can join the NCT06104852 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06104852 currently recruiting?

Yes, NCT06104852 is actively recruiting participants. Contact the research team at sstarling@adamsclinical.com for enrollment information.

Where is the NCT06104852 trial being conducted?

This trial is being conducted at Boston, United States, Watertown, United States, New York, United States.

Who is sponsoring the NCT06104852 clinical trial?

NCT06104852 is sponsored by Adams Clinical. The trial plans to enroll 600 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology